Group 1 - The total external guarantees provided by the company and its subsidiaries amount to approximately 1.656 billion yuan, which represents 30.72% of the audited net assets attributable to ordinary shareholders for the year 2024 [1] - The company has provided guarantees totaling about 1.566 billion yuan for its subsidiaries, accounting for 29.05% of the audited net assets attributable to ordinary shareholders for 2024 [1] - The amount of guarantees for entities outside the consolidated financial statements is 90 million yuan, which is 1.67% of the audited net assets attributable to ordinary shareholders for 2024 [1] Group 2 - For the first half of 2025, the revenue composition of the company is as follows: chemical preparations account for 42.67%, chemical raw materials account for 25.02%, biological preparations account for 16.71%, pharmaceutical and other logistics trade account for 6.76%, and pharmaceutical intermediates account for 6.47% [1] - The current market capitalization of the company is 10.7 billion yuan [1]

Core Viewpoint - North China Pharmaceutical has received approval from the National Medical Products Administration for the injection of Vancomycin Hydrochloride (0.5g), with a validity period until August 25, 2030 [1] Group 1: Product Information - Vancomycin Hydrochloride primarily exerts its bactericidal effect by inhibiting the biosynthesis of the bacterial cell wall [1] - The drug can alter the permeability of bacterial cell membranes and RNA synthesis [1] - It is suitable for intravenous infusion for infections caused by Methicillin-resistant Staphylococcus aureus and other bacteria, and can be taken orally for antibiotic-associated pseudomembranous colitis caused by Clostridium difficile, as well as Staphylococcal enterocolitis [1]

证券代码：600812 证券简称：华北制药 公告编号：临 2025-046 华北制药股份有限公司 关于为下属子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 本次担保金额 | 18,000 | 华药国际医药有限公司 万元 | | | --- | --- | --- | --- | --- | | 担保对象一 | 实际为其提供的担保余额 | 23,000 | 万元 | | | | 是否在前期预计额度内 | √是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | √否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 9,000 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 165,586.06 | | 对外担保总额占上市公司最近一 | 30.72 | | 期经审计净资产的比例（%） | | | | □对外担保总额超过最 ...

证券代码：600812 股票简称：华北制药 编号：临 2025-047 华北制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，华北制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的注射用盐酸万古霉素（0.5g）《药品注册证书》，现 将有关情况公告如下： | 药品名称 | | 药品通用名称：注射用盐酸万古霉素 | | | | --- | --- | --- | --- | --- | | | | 英文名/拉丁名：Vancomycin | Hydrochloride | for Injection | | 主要成分 | | 盐酸万古霉素 | | | | 剂 | 型 | 注射剂 | 申请事项 | 药品注册（境内生 产） | | 规 | 格 | 0.5g（50 万单位） （按 C66H75Cl2N9O24 计） | 注册分类 | 化学药品 4 类 | | 药品注册标准编号 | | YBH19752025 | 药品有效期 | 18 个月 | | 包装规格 | | 1 瓶/盒 | 处方药/非处方药 ...

Core Viewpoint - North China Pharmaceutical (600812.SH) has received the drug registration certificate for injectable vancomycin hydrochloride (0.5g) from the National Medical Products Administration, indicating the product meets the basic entry requirements for centralized procurement and has equivalent efficacy to the original product [1] Group 1: Product Information - Injectable vancomycin hydrochloride primarily acts by inhibiting bacterial cell wall biosynthesis and can alter bacterial cell membrane permeability and RNA synthesis [1] - The intravenous administration is suitable for infections caused by methicillin-resistant Staphylococcus aureus and other bacteria, including conditions such as sepsis, infective endocarditis, osteomyelitis, arthritis, burns, surgical wound infections, pneumonia, lung abscess, empyema, peritonitis, and meningitis [1] - The oral form is indicated for antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and staphylococcal enterocolitis [1] Group 2: Market Position and Strategy - The approval of injectable vancomycin hydrochloride enhances the company's product portfolio in the anti-infection field, building on its existing product, Vanxun (injectable deacetyl vancomycin hydrochloride) [1] - This development is expected to effectively improve the company's competitive position in the market for anti-infection products [1]

Core Viewpoint - North China Pharmaceutical (600812) has received approval from the National Medical Products Administration for the injection of Vancomycin Hydrochloride (0.5g), indicating successful completion of the consistency evaluation of quality and efficacy for generic drugs [1] Company Summary - The approved Vancomycin Hydrochloride is primarily used to inhibit bacterial cell wall biosynthesis, demonstrating bactericidal activity [1] - Vancomycin also alters the permeability of bacterial cell membranes and RNA synthesis, making it effective against infections caused by Methicillin-resistant Staphylococcus aureus and other bacteria [1]

Core Viewpoint - The company has received the drug registration certificate for injectable vancomycin hydrochloride (0.5g) from the National Medical Products Administration, indicating that the product meets the basic requirements for centralized procurement bidding and has therapeutic effects equivalent to the original product [1] Group 1 - The approval of injectable vancomycin hydrochloride (0.5g) enhances the company's product portfolio in the anti-infection field [1] - The new product complements the existing product, vancomycin (injection of vancomycin hydrochloride), thereby improving the company's offerings in the market [1]

智通财经APP讯，华北制药(600812.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的注 射用盐酸万古霉素(0.5g)《药品注册证书》。 此次公司获得注射用盐酸万古霉素(0.5g)《药品注册证书》，证明该产品具备了集采招标基本准入条 件，产品药效等同于原研产品，在公司已有产品万迅(注射用盐酸去甲万古霉素)的基础上，有效完善了 抗感染领域的产品结构。 ...

8月25日，一场聚焦医药产业创新与资本协同的高端对接会在华北制药（600812）举行。财达证券 （600906）党委书记、董事长张明携中国工程院院士团队与华北制药党委书记、董事长王立鑫等企业高 管围绕纳米新技术创新药合作、进一步推动医药产业创新与资本协同发展进行深入交流。 "我们致力于打造产业最友好的投资银行。"张明向记者阐述了财达证券的服务理念。 据介绍，该券商已为华北制药构建起包含市值管理、科创融资、股权协同、资本培育、市场开拓等五大 板块的"五位一体"服务体系。这种全链条、差异化、精准化的服务模式，正在河北省属企业中形成示范 效应。 在技术对接环节，医药院士团队带来的纳米新技术创新药方案引发关注。该技术实现了原材料进口替代 和工艺流程简化两大突破，与华北制药的转型升级需求高度契合。财达证券充分发挥桥梁作用，推动技 术入股、合作研发等多元合作模式落地。 张明表示，未来财达证券将进一步发挥投资银行功能，围绕"五大举措"全方位精准对接华北制药科技创 新、重大项目融资和市场开拓等方面金融需求，携手打造更加紧密的省属企业战略合作典范。一是持续 协助市值管理，充分发挥资本市场的价值发现和价值投资功能。二是充分把握资 ...

Group 1 - The core viewpoint of the article highlights the growth trends in China's chemical pharmaceutical industry, with a projected production increase in raw chemical drugs by 5.4% in 2025 [1] - According to the National Bureau of Statistics, the production of raw chemical drugs in China reached 333,000 tons in June 2025, reflecting a year-on-year growth of 5.4% [1] - For the first half of 2025, the cumulative production of raw chemical drugs in China was 1.92 million tons, showing a cumulative growth of 4.8% [1] Group 2 - The article lists several publicly listed companies in the pharmaceutical sector, including Heng Rui Medicine, East China Pharmaceutical, and others [1] - It references a report by Zhiyan Consulting that analyzes the supply and demand dynamics of the chemical pharmaceutical industry in China from 2025 to 2031 [1]